Piramal Pharma Teams Up With Blue-Zone on Anaesthetic Gas Tech

Piramal Pharma has announced a strategic collaboration between its subsidiary, Piramal Critical Care (PCC), and Blue-Zone Technologies to introduce a groundbreaking solution for waste anaesthetic gas recycling.

This collaboration will provide the opportunity to capture, process, and recycle waste anaesthetic gases and assist healthcare establishments in minimizing their environmental impact on preserving effective general anaesthesia in patients all over the world.

Combining the Blue-Zone application of the Phoenix Deltasorb technology with the global manufacturing and marketing facilities of this firm, PCC, in conjunction with Phoenix Deltasorb, is aiming to offer a sustainable solution to the volatile anaesthetics handling of hospitals.

Also Read: How Emerging Biotech Startups Reshaping the Bioprocessing Future

Under the arrangement, Blue-Zone shall first and foremost sell its waste anaesthetic gas capture systems to the customers of PCC in Europe, mainly in France and Germany, under the permission of the regulating authorities. The gas captured will then be used by PCC to manufacture Sevoflurane USP, an important anaesthesia product to be used in Canada.

Both firms anticipate the extension of their business activities to the other geographic areas to scale recycling and marketing of Sevoflurane USP of anaesthetic gases, which are captured. Piramal Critical Care has already become a leader in the anaesthesia, pain management and intrathecal therapy products, which are already provided to hospitals in more than 100 countries.

Financial news Piramal PHR has posted its net losses at Rs 136.19 crore in the quarter ending in December 2025, compared to a net profit of Rs 3.68 crore in the same quarter last year. Q3 FY26 outturn sales also declined by 2.92 with the outturn sales amounting to 2,139.87 crore.